DABIGATRAN – THE NEW APPROACH FOR DEEP VENOUS TROMBOSIS PROPHYLAXIS
- Authors: Minasov T.B.1, Minasov B.S.1, Zagidullin S.Z.1, Zagidullin N.S.1, Caglayan E.2, Gassanov N.2
-
Affiliations:
- ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
- Университетская клиника внутренних болезней, г. Кёльн
- Issue: Vol 17, No 3 (2011)
- Pages: 80-83
- Section: Experience exchange
- URL: https://ogarev-online.ru/2311-2905/article/view/125440
- DOI: https://doi.org/10.21823/2311-2905-2011-0-3-80-83
- ID: 125440
Cite item
Full Text
Abstract
The amount of total joint replacement is more than 1.5 mln world wide and requirement is increasing each year. Nevertheless one of the most dramatic complication after orthopedic manipulations are deep venous trombosis. As known, two aspects of prophylaxis are most important: duration of treatment and the doses of drags. The aim of study was to analys the influence of dabigatran for the risk of postop complications with the short time patients treatment complains. Treatment combination with dabigatran was clinically effective and the rate of adversing events was low. Thus we can conclude that treatment complains of dabigatran significantly higher then traditional injections of low molecular weight heparins.
About the authors
T. B. Minasov
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Author for correspondence.
Email: m004@yandex.ru
к.м.н., доцент кафедры травматологии и ортопедии Russian Federation
B. Sh. Minasov
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор, заведующий кафедрой травматологии и ортопедии Russian Federation
Sh. Z. Zagidullin
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор, заведующий кафедрой пропедевтики внутренних болезней
Russian FederationN. Sh. Zagidullin
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор кафедры пропедевтики внутренних болезней Russian Federation
E. Caglayan
Университетская клиника внутренних болезней, г. Кёльн
Email: fake@neicon.ru
старший ординатор Germany
N. Gassanov
Университетская клиника внутренних болезней, г. Кёльн
Email: fake@neicon.ru
ординатор Germany
References
- Blech, S. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans / S. Blech [et al.] // Drug. Metab. Dispos. – 2008. – Vol. 36. – P. 386–399.
- Cohen, A.T. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study / A.T. Cohen [et al.] // Lancet. – 2008. – Vol. 371. – P. 387–394.
- Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation / S.J. Connolly [et al.] // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1139–1151.
- Eriksson, B.I. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial / B.I. Eriksson [et al.] // J. Thromb. Haemost. – 2007. – Vol. 5. – P. 2178–2185.
- Eriksson, B.I. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial / B.I. Eriksson [et al.] // Lancet. – 2007. – Vol. 370. – P. 949–956.
- Hirsh, J. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range / J. Hirsh [et al.] // Chest. – 2001. – Vol. 119. – P. 8S–21S.
- Liesenfeld, K.H. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis / K.H. Liesenfeld [et al.] // Br. J. Clin. Pharmacol. – 2006. – Vol. 62. – P. 527–537.
- Hip fracture outcomes in people age fifty and over. Background paper, Office of Technology Assessment. Washington, DC: US GPO, 2004.
Supplementary files
